Commit Biologics ApS was launched in Denmark on 9 May with seed funding of €16 million to use a proprietary platform to develop new drugs for cancer and autoimmune diseases. The seed funding was provided by Bioqube Ventures and Novo Holdings. Commit is a spin-out from Aarhus University in Denmark and was initially incubated by the country’s BioInnovation Institute.
